Stay updated on Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial
Sign up to get notified when there's something new on the Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial page.

Latest updates to the Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe new screenshot shows only minor UI adjustments (layout and header styling) with no changes to core study information such as eligibility criteria, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedLocations section refreshed: a single consolidated Locations section now lists Illinois, Maryland, Pennsylvania, and Quebec, replacing the previous separate location blocks. The HHS Vulnerability Disclosure link was removed.SummaryDifference0.6%

- Check25 days agoChange DetectedVisual/UI changes are present (layout and styling adjustments) while core study details remain unchanged (eligibility criteria, outcomes, locations, etc.). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and updated the page revision to v3.3.2. The older PubMed wording was replaced.SummaryDifference0.2%

- Check48 days agoChange DetectedRemoved the site-wide notice about government funding and NIH operating status from the page; this is a non-core notification and does not affect the trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check55 days agoChange DetectedNo significant changes detected between the old and new screenshots; the page content and key details appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial page.